AIDS Activists Want NIH To Take Steps To Circumvent Truvada Patent.

Ed Silverman writes in his “Pharmalot” column for STAT (7/24) that AIDS activists are “approached the National Institutes of Health to discuss two options for sidestepping” Gilead Sciences’ patent for the expensive HIV prevention drug Truvada. One method...